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linical and Angiographic Outcome After Sirolimus-
luting Stent Implantation in Aorto-Ostial Lesions
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ntonio Colombo, MD*
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OBJECTIVES This observational study evaluated the clinical and angiographic outcomes of patients with
aorto-ostial coronary artery disease treated with sirolimus-eluting stents (SESs) or with bare
metal stents (BMSs).
BACKGROUND The safety and effectiveness of SESs for the treatment of aorto-ostial lesions have not been
demonstrated.
METHODS We identified 82 consecutive patients who underwent percutaneous coronary interventions in
82 aorto-ostial lesions using the SES (32 patients) or BMS (50 patients) and compared the
two groups of patients. The incidence of major adverse cardiac events (MACE), including
death or Q-wave myocardial infarction (MI), target lesion revascularization (TLR), and target
vessel revascularization (TVR), were recorded in-hospital and at a 10-month follow-up.
RESULTS All stents were implanted successfully. There were no statistically significant differences
regarding major in-hospital complications between the two groups. At 10-month follow-up,
two (6.3%) patients in the SES group and 14 (28%) patients in the BMS group underwent
TLR (p  0.01); MACE were less frequent in the SES group compared to the BMS group
(19% vs. 44%, p  0.02). Angiographic follow-up showed lower binary restenosis rates (11%
vs. 51%, p  0.001) and smaller late loss (0.21  0.31 mm vs. 2.06  1.37 mm, p  0.0001)
in the SES group.
CONCLUSIONS The main finding of our study is that, compared to the BMS, implantation of the SES in
aorto-ostial lesions appears safe and effective, with no increase in major in-hospital
complications and a significant improvement in restenosis and late event rates at 10-month
follow-up. (J Am Coll Cardiol 2004;44:967–71) © 2004 by the American College of
Cardiology FoundationM
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irevious studies with bare metal stents (BMSs) showed that
orto-ostial lesions have higher restenosis rates than non–
orto-ostial lesions (1–4). Traditionally, the presence of an
orto-ostial stenosis poses a special management problem
or the interventionalist in that ostial lesions are the most
ikely to be associated with suboptimal angiographic results
ue to lesion rigidity and recoil (1,2,4,5). Although stents
rovide adequate scaffolding to prevent recoil, in-stent
estenosis is mainly due to neointimal hyperplasia.
irolimus-eluting stents (SESs) (Cypher, Cordis/Johnson
Johnson, Warren, New Jersey) have been shown to
educe neointimal hyperplasia and risk of restenosis (6,7).
owever, the issue of SES implantation in aorto-ostial
esions has not been adequately evaluated, because these
atients were excluded or minimally represented in the
ulticenter randomized trials versus patients treated with
MSs. The purpose of this study was to evaluate the safety
nd effectiveness of the SES implantation in aorto-ostial
esions.
From the *Centro Cuore Columbus and †San Raffaele Hospital, Milan, Italy.
Manuscript received April 9, 2004, revised manuscript received May 10, 2004,mccepted May 18, 2004.ETHODS
e evaluated retrospectively 32 consecutive patients who
nderwent percutaneous coronary interventions in 32 aorto-
stial lesions using the SES between April 2002 and March
003. A control group for comparison was composed of 50
onsecutive patients who underwent treatment of aorto-
stial lesions (50 lesions) with the BMS during the period
mmediately before the introduction of the SES. The
ollowing BMSs were used: BX Sonic or BX Velocity
Cordis/Johnson & Johnson) in 28%; JoMed polytetrafluo-
oethylene (PTFE)-covered stent (JoMed, Rangendingen,
ermany) in 14%; Multi-Link Penta (Guidant Corp.,
anta Clara, California) in 10%; Diamond-Flex (Phytis,
reieich, Germany) in 10%; Multi-Link Tetra (Guidant
orp.) in 5%; Sorin Carbon (Sorin Biomedica, Saluggia,
taly) in 8%; and other stents in 27%.
All patients were pre-treated with ticlopidine or clopi-
ogrel and aspirin at least three days before the procedure;
loading dose of 300 mg clopidogrel was administered to
hose who were not pre-treated. Aspirin was continued
ndefinitely and clopidogrel or ticlopidine for at least threeonths after SES and for one month following BMS
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Sirolimus-Eluting Stents in Aorto-Ostial Lesions September 1, 2004:967–71mplantation. Stent implantation methods have been de-
cribed previously (8). All stents were implanted with
igh-pressure (12 atm) final balloon dilatation with an
ttempt to fully cover the angiographic lesion and to ensure
omplete stent apposition.
Glycoprotein IIb/IIIa inhibitors were administered at the
perator’s discretion.
ngiographic analysis. Cineangiograms were analyzed us-
ng a validated edge detection system (Version 5.2, CMS,
EDIS, The Netherlands). Standard qualitative and quan-
itative definitions and measurements were used. Using the
ontrast-filled catheter as the calibration standard, minimal
umen diameter (MLD), reference diameter, and percent
iameter stenosis (DS) before and after coronary interven-
ion were obtained from the single “worst” and least
Table 1. Baseline Clinical and Angiographic C
Patient characteristics
Patients (n)
Male gender, n (%)
Age (yrs)
Unstable angina, n (%)
Diabetes, n (%)
Hypertension, n (%)
Hypercholesterolemia, n (%)
Family history of coronary artery disease, n (%)
Current smoking, n (%)
Previous MI, n (%)
Previous PCI, n (%)
Previous bypass surgery, n (%)
Multivessel disease, n (%)
Left ventricular ejection fraction, n (%)
Lesion characteristics
Lesions (n)
Vessels treated
Left main artery, n (%)
Right coronary artery, n (%)
Saphenous vein graft, n (%)
Lesion characteristics
Calcium, n (%)
Eccentric, n (%)
In-stent restenosis, n (%)
Pre-intervention TIMI flow grade 0 to 2, n (
Total occlusion, n (%)
Thrombus, n (%)
Values are presented as numbers, (relative percentages), or m
BMS  bare metal stent; MI  myocardial infarction; PC
Abbreviations and Acronyms
BMS  bare metal stent
DS  diameter stenosis
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal lumen diameter
PTFE  polytetrafluoroethylene
SES  sirolimus-eluting stent
TLR  target lesion revascularization
TVR  target vessel revascularizationstent; TIMI  Thrombolysis In Myocardial Infarction.oreshortened view. Aorto-ostial lesions were defined as
esions involving the junction between the aorta and the
rifice of the right coronary artery, left main, or a saphenous
ein graft within 3 mm of the vessel ostia.
Angiographic success was defined as a final residual
tenosis less than 30%. Angiographic restenosis was defined
s 50% DS by quantitative coronary angiography within a
reviously stented vessel segment. Late lumen loss was
efined as the difference between the MLD at the comple-
ion of the stenting procedure and that measured at follow-
p. These are standard qualitative and quantitative analyses
nd definitions, and they have been published previously (9).
linical definitions and follow-up. Pre-specified clinical
nd laboratory demographic information was obtained from
ospital charts that were reviewed by independent research
ersonnel; data were entered prospectively into a dedicated
atabase. Standard definitions included: 1) Q-wave myo-
ardial infarction (MI): the presence of new pathological Q
aves in the electrocardiogram associated with an elevation
f cardiac enzyme 2 times the upper normal value, and 2)
on–Q-wave MI: creatine kinase-MB enzyme elevation3
imes the upper normal value without new Q waves.
Clinical follow-up was performed by either telephone
ontact or office visit. Major adverse cardiac events
MACE) were recorded, including death (all-cause),
-wave MI, and target lesion revascularization (TLR) and
cteristics
SES BMS p Value
32 50
27 (84) 41 (82) 0.7
62  10 63  11 0.9
8 (25) 22 (44) 0.06
3 (9.4) 6 (12) 0.7
22 (69) 21 (42) 0.02
22 (69) 20 (40) 0.01
11 (34) 11 (22) 0.2
5 (15) 14 (22) 0.2
11 (36) 27 (54) 0.1
22 (69) 38 (76) 0.4
10 (31) 21 (42) 0.3
22 (69) 39 (77) 0.7
51  8 55  9 0.04
32 50
0.4
10 (31) 10 (20)
17 (53) 28 (56)
5 (16) 12 (24)
4 (13) 6 (12) 0.9
16 (67) 32 (64) 0.8
12 (38) 11 (22) 0.2
8 (25) 6 (12) 0.2
2 (6) 1 (2) 0.3
0 3 (6) 0.1
SD.
ercutaneous coronary intervention; SES  sirolimus-elutinghara
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September 1, 2004:967–71 Sirolimus-Eluting Stents in Aorto-Ostial Lesionsarget vessel revascularization (TVR) (whether percutaneous
r surgical).
tatistical analysis. Statistical analysis was performed us-
ng SPSS, version 11 (SPSS Inc., Chicago, Illinois). Con-
inuous variables are expressed as mean 1 SD and cate-
orical variables as frequency (%). Continuous variables
ere compared using independent samples t test. Categor-
cal variables were compared with chi-square statistics.
ESULTS
aseline patient and lesion characteristics. The baseline
linical and lesion characteristics of the patient population
ere similar between the two groups, except for a higher
ncidence of hypertension and hypercholesterolemia and a
ower mean ejection fraction in the SES group (Table 1).
atients with the BMS had a trend toward higher incidence
f unstable angina. Out of the 20 left main coronary artery
esions, 9 (45%) were unprotected; 5 in the SES and 4 in the
MS group.
rocedural data and in-hospital outcome. The proce-
ural data and in-hospital outcome are shown in Table 2.
ll stents were deployed successfully. The SES group,
ompared to the BMS, had a smaller mean maximum
alloon diameter (3.50 vs. 3.82 mm, p  0.003) and a
onger mean stent length per lesion (24.81 vs. 13.71 mm, p
0.0001).
There were no statistically significant differences regard-
ng procedural and major in-hospital complications. All
rocedures except one (2%) of the BMS group resulted in
hrombolysis In Myocardial Infarction (TIMI) flow grade
Table 2. Procedural Data and In-Hospital Ou
Procedural characteristics
Procedures (n)
Maximum balloon diameter (mm)
Maximum balloon inflation (atm) 1
Stent length per lesion (mm) 2
Stents per lesion
Debulking, n (%)
Cutting balloon, n (%)
Glycoprotein IIb/IIIa inhibitors, n (%)
Procedural complications
Intra-aortic balloon pump, n (%)
Acute stent thrombosis, n (%)
TIMI flow grade 0 to 2, n (%)
Dissection after stent, n (%)
Perforation, n (%)
In-hospital outcome
Angiographic success, n (%)
Death, n (%)
Q-wave MI, n (%)
Non–Q-wave MI, n (%)
Stroke, n (%)
Emergency bypass surgery, n (%)
Repeat PCI, n (%)
Values are presented as numbers (relative percentages), or m
Abbreviations as in Table 1.. There were no cases of acute stent thrombosis, perfora- rions, or residual dissections. One (3.1%) patient in the SES
roup suffered a nonfatal, in-hospital Q-wave MI. Non–Q-
ave MI occurred in three (9.3%) SES patients compared to
even (14%) of the BMS group (p  0.7).
linical outcome. One-month follow-up was available in
ll patients, and no additional events (including subacute
hrombosis) were recorded (data not shown). Ten-month
umulative clinical follow-up was available in all patients
nd is shown in Figure 1. Patients with the SES had lower
LR compared to patients with the BMS (6.3% vs. 28%, p
0.03). One patient of the SES group suffered late-stent
hrombosis presented as an acute MI and died four months
ost-procedure after discontinuation of antiplatelet therapy.
here was a trend toward less frequent TVR in the SES
roup (16% vs. 34%, p  0.06). In addition, the incidence
e
ES BMS p Value
32 50
 0.40 3.82 0.49 0.003
 3.12 18.28  3.94 0.6
 16.25 13.71  5.57 0.0001
 0.47 1.02 0.33 0.07
(3.1) 3 (6) 0.9
(22) 12 (24) 0.9
(31) 11 (22) 0.5
(3.1) 1 (2) 0.7
0 0 0
0 1 (2) 0.8
0 1 (2) 0.8
0 0
NS
(100) 50 (100) 1.0
0 0 NS
(3.1) 0 0.1
(9.3) 7 (14) 0.7
0 0 NS
0 0 NS
0 0 NS
SD.
igure 1. Cumulative clinical outcome at 10-month follow-up. Black bars
bare metal stent; lined bars  sirolimus-eluting stent. MACE  major
dverse cardiac events; MI  myocardial infarction; TLR  target lesiontcom
S
3.50
7.84
4.81
1.18
1
7
10
1
32
1
3
ean evascularization; TVR  target vessel revascularization.
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Sirolimus-Eluting Stents in Aorto-Ostial Lesions September 1, 2004:967–71f 10-month MACE was significantly lower in the SES
ompared to the BMS group (19% vs. 44%, p  0.02).
uantitative coronary angiography. Quantitative coro-
ary angiographic analysis is shown in Table 3. The mean
eference vessel diameter was 3.17 mm for the SES and 3.47
m for the BMS group (p  0.1). The SES group had a
rend (p  0.07) toward smaller MLD compared to the
MS group. Post-intervention reference vessel diameter
nd MLD were significantly larger in the BMS group.
Angiographic follow-up was available in 88% of the SES
atients versus 70% of the BMS patients (p  0.1). The
ean time to angiographic follow-up did not differ signif-
cantly between the two groups (7.4 vs. 6.3 months, p 
.08). The rate of restenosis for the lesions treated with
TFE stents was 50% (three of six lesions with available
ngiographic follow-up) and did not differ significantly from
he restenosis rate of the other stents of the BMS group
52%, p 0.7). Binary restenosis occurred less frequently in
he SES group (11% vs. 51%, p  0.001). All three
estenotic lesions in the SES group were focal (10 mm in
ength). Conversely, only 9 (50%) of the 18 restenotic
esions in the BMS group were focal. In addition, late loss
as significantly smaller in the SES compared to the BMS
roup (0.21  0.31 mm vs. 2.06  1.37 mm, p  0.0001).
ISCUSSION
he main finding of our study is that, compared to the
MS, implantation of the SES in aorto-ostial lesions
ppears safe and effective, with no increase in major in-
ospital complications and a significant improvement in
estenosis and late event rates at 10-month follow-up.
The findings of the current study are similar to the results
f the major drug-eluting stent randomized trials, which
nvariably showed dramatic decrease in restenosis rates with
Table 3. Quantitative Coronary Angiography a
Quantitative Coronary
Angiography SES
Lesions (n) 32
Pre-intervention
RVD (mm) 3.17
MLD (mm) 1.09
DS (%) 66 
Lesion length (mm) 10.20
Post-intervention
RVD (mm) 3.59
MLD (mm) 3.18
DS (%) 11 
Follow-up
Angiography done, n (%) 28 (88
RVD (mm) 3.61
MLD (mm) 3.13
DS (%) 15 
Late loss (mm) 0.21 
Restenosis, n (%) 3 (11
Values are presented as numbers, (relative percentages), or m
DS  diameter stenosis; MLD  minimal lumen diam
Table 1.he use of the SES (6,7). As expected, late loss in the SES group was significantly smaller compared to the BMS
roup. However, the mean late loss of 0.21 mm was slightly
arger than the respective values of the landmark random-
zed trials of the SES versus the BMS. More specifically, the
ean late loss was0.01 mm in the RAVEL (Randomized
tudy with the sirolimus-eluting Bx VELocity balloon-
xpandable stent) and 0.17 mm in the SIRIUS (A U.S.
ulticenter, randomized, double-blind study of the
IRolImUS-eluting stent in de novo native coronary le-
ions) (6,7). Lesion rigidity might be a possible explanation
or this finding. Histologic data from pathologic series (10)
nd atherectomy specimens (11) showed that ostial lesions
re frequently heavily calcified, fibrotic, and sclerotic. It has
lso been suggested that there may be more elastic recoil
ven after stent implantation at ostial sites because of the
ighly elastic tissue in the adjacent aortic wall (1,10).
herefore, stenting at ostial site may respond differently
han other segments of the coronary artery. Furthermore,
he nonavailability of 3.5-mm SES (seven-cell stent) in our
enter at the time of patient enrollment for the present study
ay have resulted in a slight mismatch of the vessel size and
he stent diameter and thus to stent overexpansion or less
omogeneous drug distribution in the SES group.
In our study, the SES group had significantly smaller
ost-intervention MLD compared to the BMS group; thus
t consisted of lesions more prone to restenosis. Further-
ore, 38% of the SES lesions were restenotic compared to
2% of the BMS lesions (p  0.2). The discrepancy in the
ES group between the TLR rate of 6.3% and the TVR rate
f 16% is due to treatment of other lesions distal to the
tented segments which were not stented at the time of the
ndex procedure.
tudy limitations. The major limitations of this study are
he small sample size, the different percentages of angio-
seline, After Intervention, and at Follow-Up
BMS p Value
50
3.47  0.74 0.1
1.48  0.74 0.07
58  17 0.1
8.47  4.01 0.1
3.97  0.51 0.01
3.66  0.53 0.005
9  7 0.2
35 (70%) 0.1
3.50  0.83 0.6
1.60  1.36 0.0001
55  34 0.0001
2.06  1.37 0.0001
18 (51) 0.001
standard deviation.
VD  reference vessel diameter; other abbreviations as int Ba
0.59
0.69
19
7.27
0.52
0.55
7
%)
0.43
0.59
13
0.31
)
ean 
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September 1, 2004:967–71 Sirolimus-Eluting Stents in Aorto-Ostial Lesionsisk factors for restenosis. The lack of randomization is a
roblem difficult to solve in view of the proven efficacy of
rug-eluting stents. The discrepancy in angiographic
ollow-up between the two groups (88% for SES vs. 70% for
MS) might have skewed the results in favor of the BMS
roup, because it is well known that angiographic follow-up
riggers repeat interventions (12). However, this difference
as statistically significant, nor was the difference in the
ean time to angiographic follow-up (7.4  3.0 months vs.
.3  2.7 months, p  0.08 for SES and BMS, respec-
ively). It is worth noting that the majority of the patients
ho had restenosis were symptomatic or had evidence of
schemia (72% of the BMS vs. 67% of the SES group, p 
.6). Among the variables affecting restenosis, diabetes and
nstable angina were present more frequently in the BMS
roup, whereas other lesion variables associated with reste-
osis were slightly more frequent in the SES group.
ONCLUSIONS
he main finding of our study is that, compared to the
MS, implantation of the SES in aorto-ostial lesions
ppears safe and effective, with no increase in major in-
ospital complications and a significant improvement in
estenosis and late event rates at 10-month follow-up.
eprint requests and correspondence: Dr. Antonio Colombo,
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